| Q93166790 | ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models |
| Q24538811 | ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia |
| Q97551921 | ACE2, the Receptor that Enables the Infection by SARS-CoV-2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators |
| Q91703665 | Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System |
| Q90027115 | Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics |
| Q94587433 | Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019 |
| Q97075901 | Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers |
| Q51820362 | Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. |
| Q46068140 | Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes |
| Q92070664 | COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities |
| Q92103416 | COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities |
| Q98779021 | COVID-19 and Central Nervous System: Entry Routes And |
| Q97636658 | COVID-19 and Myocarditis: What Do We Know So Far? |
| Q110566803 | COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation |
| Q97636279 | COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives |
| Q90092121 | COVID-19 and the cardiovascular system |
| Q99240645 | COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications |
| Q95276824 | COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches |
| Q91717735 | COVID-19: Risk Groups, Mechanistic Insights, and Challenges |
| Q99553587 | Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19? |
| Q91931325 | Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? |
| Q98648527 | Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study) |
| Q40329899 | Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart |
| Q97093986 | Cardiovascular disease management during the coronavirus disease 2019 pandemic |
| Q99631931 | Cardiovascular involvement in COVID-19: not to be missed |
| Q96612393 | Cardiovascular manifestations in severe and critical patients with COVID-19 |
| Q91996603 | Characteristic Electrocardiographic Manifestations in Patients With COVID-19 |
| Q98155172 | Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis |
| Q40231729 | Computational characterization and design of SARS coronavirus receptor recognition and antibody neutralization |
| Q94671925 | Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| Q99597189 | Coronavirus disease-19 and cardiovascular disease: A risk factor or a risk marker? |
| Q52017432 | Developmental expression of ACE2 in the SHR kidney: a role in hypertension? |
| Q95300834 | Diabetes and metabolic syndrome as risk factors for COVID-19 |
| Q36817565 | Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges. |
| Q94562917 | Epidemiological analysis of the early 38 fatalities in Hubei, China, of the coronavirus disease 2019 |
| Q92040628 | Epidemiology and clinical features of COVID-19: A review of current literature |
| Q98224247 | Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels |
| Q47752741 | Good ACE, bad ACE do battle in lung injury, SARS. |
| Q41786103 | Human recombinant ACE2 reduces the progression of diabetic nephropathy |
| Q35025287 | Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors |
| Q40399203 | Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis |
| Q91719430 | Inside the heart of COVID-19 |
| Q93270479 | Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19 |
| Q94602018 | Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic |
| Q35088385 | Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis |
| Q36935327 | Modulation of glomerulosclerosis |
| Q99630284 | Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease |
| Q96647283 | Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review |
| Q37660786 | New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism |
| Q94460600 | Novel Coronavirus disease (COVID-19) in newborns and infants: what we know so far |
| Q96302226 | Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement |
| Q36846526 | PAI-1 and kidney fibrosis |
| Q94466083 | Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19 |
| Q34645944 | Preparative Purification of Linarin Extracts from Dendranthema indicum Flowers and Evaluation of Its Antihypertensive Effect |
| Q99202266 | Psychological, addictive, and health behavior implications of the COVID-19 pandemic |
| Q35011434 | Recently discovered human coronaviruses |
| Q38750210 | Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease |
| Q98771893 | Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review |
| Q37884450 | Role of ACE2 in diastolic and systolic heart failure. |
| Q37081415 | Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure |
| Q94547449 | SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment |
| Q94492553 | SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications |
| Q44282005 | SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. |
| Q36415424 | Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention |
| Q37089449 | Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition |
| Q91977604 | The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments |
| Q34010888 | The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. |
| Q93237239 | The pivotal link between ACE2 deficiency and SARS-CoV-2 infection |
| Q94656864 | The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses |
| Q36663074 | Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. |
| Q36776835 | Virus-mediated modulation of the host endocrine signaling systems: clinical implications |